Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384223 | 0.86 | POLB (0.61) | POLBMAPTLMNAHTTUSP2 | |
| SCHEMBL1575401 | 0.85 | GRIN2B (0.45) | POLBS1PR2PAK1ADRB1MAPT | |
| SCHEMBL655599 | 0.85 | POLB (0.63) | POLBMAPTHPGDS | |
| Hydrochloric Acid SCHEMBL23246046 | 0.84 | POLB (0.66) | POLBMAPTHPGDS | |
| SCHEMBL29185308 | 0.82 | S1PR2 (0.51) | S1PR2PAK1MAPTLMNAHTT | |
| SCHEMBL8219109 | 0.81 | S1PR2 (0.50) | S1PR2PAK1MAPTLMNAHTT | |
| SCHEMBL3072567 | 0.80 | MAPT (0.59) | POLBMAPTHPGDS | |
| SCHEMBL1441236 | 0.78 | LMNA (0.52) | POLBMAPTLMNA | |
| SCHEMBL15844894 | 0.78 | TACR1 (0.52) | ADRB1P2RX1CYP3A4 | |
| Hydrochloric Acid SCHEMBL28861578 | 0.78 | POLB (0.58) | POLBMAPTHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | POLB 3691/4885S1PR2 1136/4885PAK1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.